Similar to what we observed previously, MRTX849 + anti–PD-1 led to short-term tumor control after 1 week on treatment and extended survival, but, eventually, tumors relapsed, and nearly all mice reached their end point within 5 to 6 weeks (Fig. 8, A and B) (8). The gene discussed is PDCD1; the disease is neoplasm.